How Testosterone Enanthate Affects Haemoglobin

Testosterone increases haemoglobin through the same erythropoietic pathways that raise haematocrit:

1. EPO upregulation: Testosterone stimulates renal erythropoietin production, signalling the bone marrow to increase red blood cell synthesis. More red blood cells means more haemoglobin in circulation.
2. Hepcidin suppression: Androgens suppress hepcidin, the master iron-regulatory peptide. Lower hepcidin increases intestinal iron absorption and mobilises iron from storage, making more iron available for haemoglobin synthesis.
3. Direct marrow stimulation: Androgen receptors on erythroid progenitor cells in the bone marrow promote proliferation and differentiation of red blood cell precursors.

Haemoglobin and haematocrit rise in tandem because haematocrit is largely determined by the total red blood cell mass, which is directly proportional to haemoglobin content. A 1 g/dL rise in haemoglobin corresponds to roughly a 3% rise in haematocrit.

Replacement doses (100-200 mg/week):

• Haemoglobin typically rises 1-2 g/dL within 3-6 months
• Most men stabilise between 15.5-17.5 g/dL
• Pre-TRT anaemic men may see a beneficial normalisation (this is actually therapeutic in hypogonadal anaemia)

Supraphysiological doses (300-600+ mg/week):

• Haemoglobin can rise 2-4 g/dL above baseline
• Values exceeding 18-19 g/dL are common in blast cycles
• The rise is more rapid, often noticeable within 6-8 weeks

Timing: Haemoglobin begins rising within 2-4 weeks and typically peaks at 3-6 months. The increase persists for as long as testosterone is administered. After discontinuation, haemoglobin gradually returns to baseline over 2-4 months as old red blood cells (120-day lifespan) are cleared without replacement at the same rate.

Baseline: Obtain a full CBC before starting testosterone. Note your pre-treatment haemoglobin as a reference point.

First year: Check haemoglobin (as part of CBC) every 3 months, drawn at trough.

Stable patients: Every 6 months once haemoglobin has been stable for two consecutive checks.

Clinical thresholds:

• Normal male range: 13.5-17.5 g/dL
• Mild elevation: 17.5-18.5 g/dL (increased monitoring)
• Significant elevation: above 18.5 g/dL (intervention required)
• The WHO defines polycythemia as haemoglobin above 16.5 g/dL in men, though most TRT clinicians use higher thresholds

Paired interpretation: Always interpret haemoglobin alongside haematocrit. If one is elevated but the other is normal, consider hydration status or lab error.

If haemoglobin is 17.5-18.5 g/dL:

• Increase injection frequency to reduce testosterone peaks
• Ensure adequate hydration (dehydration concentrates haemoglobin readings)
• Consider naringin 500-1000 mg/day for mild EPO modulation
• Recheck in 4-6 weeks

If haemoglobin exceeds 18.5 g/dL:

• Reduce testosterone dose by 10-20%
• Therapeutic phlebotomy: removing 450-500 mL of blood lowers haemoglobin by approximately 1 g/dL
• Blood donation is an effective and socially beneficial strategy (if eligible)
• Recheck 2-4 weeks after phlebotomy

If haemoglobin exceeds 20 g/dL:

• Urgent medical evaluation; this level carries serious thrombotic risk
• Pause testosterone until haemoglobin drops to a safer range
• Serial phlebotomy may be required

Important nuance: Haemoglobin is a more physiologically meaningful marker than haematocrit because it directly reflects oxygen-carrying capacity. Some clinicians prefer tracking haemoglobin over haematocrit for this reason.